Sarilumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Juvenile Idiopathic Arthritis · Phase 2

Also approved (4)
US
  • Polymyalgia Rheumatica (PMR) KEVZARA is indicated for treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
  • Polyarticular Juvenile Idiopathic Arthritis (pJIA) KEVZARA is indicated for treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh 63 kg or greater.
Product first approved 2017Outside this platform's coverageFDA label
JP
  • Treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments
Product first approved 2017PMDA
EU
  • Rheumatoid arthritisKevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate. Polymyalgia rheumaticaKevzara is indicated for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a...
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT03535402 · Gaylis, Norman B., M.D.
2018-06-01 – 2020-12-30 · Rheumatoid Arthritis
What this study did
NCT02057250 · Sanofi
2014-03 – 2016-03 · RA
What this study did
NCT02121210 · Sanofi
2014-06 – 2015-05 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07286214 · Sanofi
2026-05-12 – 2029-07-16 · Polymyalgia Rheumatica
What this study did
NCT02735707 · UMC Utrecht
2016-04-11 – 2029-02 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
What this study did
NCT03600818 · Sanofi
2018-10-09 – 2021-05-19 · Polymyalgia Rheumatica
What this study did
NCT04327388 · Sanofi
2020-03-28 – 2020-09-02 · Corona Virus Infection
What this study did
Phase 2/3 (4)
Rheumatoid Arthritis
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT04324073 · Assistance Publique - Hôpitaux de Paris
2020-03-27 – 2020-09-24 · Corona Virus Infection
What this study did
NCT04315298 · Regeneron Pharmaceuticals
2020-03-18 – 2020-09-02 · COVID-19
What this study did
Phase 2 (17)
Rheumatoid Arthritis
NCT01217814 · Sanofi
2010-11 – 2011-09 · Rheumatoid Arthritis
What this study did
Systemic Juvenile Idiopathic Arthritis
NCT02991469 · Sanofi
2018-08-09 – 2031-01-17 · Juvenile Idiopathic Arthritis
What this study did
Other / comorbidity
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07836101 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-12 – 2029-12 · Any Advanced Solid Tumors
What this study did
NCT05428007 · NYU Langone Health
2023-02-02 – 2028-03-17 · Melanoma, Unresectable Melanoma
What this study did
NCT02776735 · Sanofi
2016-09-06 – 2023-12-27 · Juvenile Idiopathic Arthritis
What this study did
NCT03770273 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-06-19 – 2023-07-31 · Indolent Systemic Mastocytosis
What this study did
NCT04008069 · Stanford University
2019-09-03 – 2022-09-09 · Sarcoidosis
What this study did
NCT04359901 · Westyn Branch-Elliman
2020-04-10 – 2021-08-02 · COVID
What this study did
NCT04357860 · Maimónides Biomedical Research Institute of Córdoba
2020-04-28 – 2021-04-06 · SARS-CoV 2, SARS
What this study did
NCT04661527 · Clinica Universidad de Navarra, Universidad de Navarra
2020-04-22 – 2020-12-30 · COVID-19 Drug Treatment
What this study did
NCT04357808 · Maria del Rosario Garcia de Vicuña Pinedo
2020-04-13 – 2020-12-04 · Covid-19
What this study did
NCT07196306 · BayCare Health System
2020-05-07 – 2020-10-15 · COVID, COVID-19, Corona Virus Infection
What this study did
NCT04322773 · Marius Henriksen
2020-04-05 – 2020-10-08 · Corona Virus Disease
What this study did
NCT01900431 · Sanofi
2013-10 – 2016-04 · Uveitis
What this study did
NCT01118728 · Sanofi
2010-06 – 2011-12 · Ankylosing Spondylitis
What this study did
NCT01061723 · Sanofi
2010-02 – 2011-06 · Ankylosing Spondylitis
What this study did
Phase 1/2 (4)
Rheumatoid Arthritis
NCT07704580 · Sanofi
2026-07-02 – 2028-10-26 · Rheumatoid Arthritis
What this study did
NCT04842981 · University of Southern Denmark
2021-05-25 – 2022-09-30 · Arthritis, Rheumatoid, Interaction
What this study did
Other / comorbidity
NCT03679845 · Massachusetts General Hospital
2019-09-01 – 2021-06-30 · Morphea, Plaque Form
What this study did
Phase 1 (12)
Rheumatoid Arthritis
NCT02404558 · Sanofi
2015-05 – 2016-03 · Rheumatoid Arthritis
What this study did
NCT02017639 · Sanofi
2014-01 – 2016-03 · Rheumatoid Arthritis
What this study did
NCT02097524 · Regeneron Pharmaceuticals
2014-03 – 2015-04 · Rheumatoid Arthritis
What this study did
NCT01850680 · Sanofi
2013-04 – 2013-12 · Rheumatoid Arthritis
What this study did
NCT01328522 · Sanofi
2011-05 – 2011-09 · Rheumatoid Arthritis
What this study did
NCT01011959 · Regeneron Pharmaceuticals
2008-12 – 2009-08 · Rheumatoid Arthritis
What this study did
NCT01026519 · Regeneron Pharmaceuticals
2008-09 – 2009-05 · Rheumatoid Arthritis
What this study did
NCT01055899 · Regeneron Pharmaceuticals
2008-07 – 2009-03 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07484113 · Stanford University
2026-09 – 2028-05 · cGVHD
What this study did
NCT04386239 · ASST Fatebenefratelli Sacco
2021-01-01 – 2023-01-01 · COVID19
What this study did
Phase 4 (2)
Rheumatoid Arthritis
NCT04350216 · Instituto de Investigación Marqués de Valdecilla
2020-04-30 – 2021-04-30 · Rheumatoid Arthritis, Atherosclerosis
What this study did
NCT03449758 · Sanofi
2018-03-05 – 2019-07-31 · Rheumatoid Arthritis
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Rheumatoid Arthritis
Other / comorbidity
NCT03600805 · Sanofi
2018-11-20 – 2020-11-24 · Giant Cell Arteritis
What this study did
Appears in other studies (6)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Other / comorbidity
NCT04341870 · Assistance Publique - Hôpitaux de Paris
2020-04-11 – 2020-08 · COVID19, SARS-CoV-2 Infection
What this study did
Phase 2 (2)
Other / comorbidity
NCT07154290 · Regeneron Pharmaceuticals
2026-03-18 – 2030-06-10 · Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
What this study did
NCT06787612 · Regeneron Pharmaceuticals
2025-05-28 – 2028-06-30 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT07850921 · Regeneron Pharmaceuticals
2027-06-28 – 2031-07-28 · Metastatic Castration-Resistant Prostate Cancer, mCRPC
What this study did
NCT04590326 · Regeneron Pharmaceuticals
2020-12-08 – 2028-11-08 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
What this study did
NCT03564340 · Regeneron Pharmaceuticals
2018-05-21 – 2027-05-10 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sarilumab: this drugApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106)
NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2%
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%)
NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther).
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33%
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are non-efficacy only in this race
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
AnakinraApprovedProtein / enzyme therapeuticInterleukin-1 Receptor AntagonistWeak signalNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2Reliable signal
NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001)
NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001)
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalFeatured results are non-efficacy only in this race
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistReliable signal
NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118)
NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals.
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Partial signal
NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81%
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant.
NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177.
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphaPartial signalFeatured results are non-efficacy only in this race
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are pharmacokinetic only in this race
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic InhibitorPartial signal
NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015).
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Partial signalFeatured results are pharmacokinetic only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic AntibodyReliable signal
NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3%
NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate.
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20Reliable signal
NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%).
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001
NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7)
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Weak signalFeatured results are non-efficacy only in this race
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints.
NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX
AcellbiaPhase 3Monoclonal antibodyCD20Reliable signal
NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%)
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
HLX01 (Hanlikang)Phase 3Monoclonal antibodyCD20Reliable signalNo reviewed efficacy summary in this indication
IguratimodPhase 3—NF-kBPartial signal
NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013).
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptorReliable signal
NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AZD1163Phase 2Biologic (subtype unspecified)PAD2 and PAD4 (peptidyl arginine deiminase 2/4)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CKD-506Phase 2Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed
Denosumab (Prolia)Phase 2Monoclonal antibodyRANKLPartial signal
NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045.
NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months.
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
JAB-8263Phase 2Small moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
NatrunixPhase 2Monoclonal antibodyIL-1 alphaPartial signalNo reviewed efficacy summary in this indication
RavagalimabPhase 2Monoclonal antibodyCD40not yet gradedNo reviewed efficacy summary in this indication
RosnilimabPhase 2Monoclonal antibodyPD-1 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045Phase 2UndisclosedPD-1not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD6912Phase 1RNA / oligonucleotideComplement Factor B (CFB) mRNAWeak signalNo reviewed efficacy summary in this indication
BMS-986454Phase 1—PAD4 (peptidylarginine deiminase 4)not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CND261Phase 1Biologic (subtype unspecified)CD20 x CD3not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 20 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sarilumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
Phase 1Lung CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT05704634 · CT.gov ↗
What to watch
March 2028 (3)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
Phase 2Systemic Juvenile Idiopathic ArthritisRecruiting
Est. primary completion 2028-03-01 · NCT02991469 · CT.gov ↗
What to watch
Phase 2Melanoma, Unresectable MelanomaRecruiting
Est. primary completion 2028-03-17 · NCT05428007 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1cGVHDNot yet recruiting
Est. primary completion 2028-05 · NCT07484113 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP) …Recruiting
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1/2Rheumatoid ArthritisRecruiting
Est. primary completion 2028-10-26 · NCT07704580 · CT.gov ↗
What to watch
2029 (2)
June 2029 (1)
Phase 3Polymyalgia RheumaticaRecruiting
Est. primary completion 2029-06-04 · NCT07286214 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Any Advanced Solid TumorsNot yet recruiting
Est. primary completion 2029-08 · NCT07836101 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch

See the full readout calendar ↗